Business & Finance2d
FDI of the Month January 2025: GSK exceeds Q4 estimates
GSK, a British drugmaker, recently beat Q4 earnings estimates. The company is our FDI of the Month January 2025.
Growing optimism and a £2bn investor payout is a shot in the arm for this British giant
Last week’s full-year results from GlaxoSmithKline (GSK) do not answer every concern the sceptics may have regarding current ...
IRS agents are asked to help with immigration crackdown
The Department of Homeland Security is asking for the Internal Revenue Service to help crack down on immigration, according ...
GSK to grow Massachusetts work force with move from Maryland
The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...
Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise
Despite a mixed fourth-quarter revenue performance, British pharmaceutical giant GSK remains optimistic about its long-term growth prospects, particularly with its ambitious revenue target for 2031.